Literature DB >> 20686848

Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers.

Alfonso López-Ruiz1, Cristina del Peso-Gilsanz, Amparo Meoro-Avilés, José Soriano-Palao, Alberto Andreu, Juan Cabezuelo, José L Arias.   

Abstract

Case (description) the patient is a 20 years old male smoker, who was diagnosed with type 2 diabetes mellitus in 2006. Due to the inadequate response to the previously established treatment, the pharmacotherapy was modified by introducing exenatide (up to 10 μg, twice daily) instead of insulin glargine, but maintaining the treatment with the diuretic and angiotensin II receptor antagonist drugs. Two months later, the patient exhibited a very important intolerance to exenatide (continuous nausea, vomiting, and dehydration), finally leading to ischemic acute renal failure. When the angiotensin II receptor antagonist and exenatide were suspended, a very rapid recovery of renal function was observed. Conclusion ischemic acute renal failure is supposed to be the consequence of the extracellular volume contraction caused by exenatide (the result of continuous nausea and vomiting). This adverse effect could be caused by the co-administration of diuretics and angiotensin II receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686848     DOI: 10.1007/s11096-010-9423-8

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  10 in total

1.  Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.

Authors:  Dennis Kim; Leigh MacConell; Dongliang Zhuang; Prajakti A Kothare; Michael Trautmann; Mark Fineman; Kristin Taylor
Journal:  Diabetes Care       Date:  2007-03-12       Impact factor: 19.112

2.  Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis.

Authors:  Leonard C Glass; Yongming Qu; Sheila Lenox; Dennis Kim; Jeffrey R Gates; Robert Brodows; Michael Trautmann; Richard M Bergenstal
Journal:  Curr Med Res Opin       Date:  2008-01-23       Impact factor: 2.580

3.  Exenatide may aggravate moderate diabetic renal impairment: a case report.

Authors:  Odd Erik Johansen; Rolf Whitfield
Journal:  Br J Clin Pharmacol       Date:  2008-05-15       Impact factor: 4.335

4.  Exenatide-associated ischemic renal failure.

Authors:  Wolfgang J Weise; Mala S Sivanandy; Clay A Block; Richard J Comi
Journal:  Diabetes Care       Date:  2009-02       Impact factor: 19.112

5.  Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.

Authors:  C M Edwards; S A Stanley; R Davis; A E Brynes; G S Frost; L J Seal; M A Ghatei; S R Bloom
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-07       Impact factor: 4.310

6.  Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.

Authors:  Orville G Kolterman; John B Buse; Mark S Fineman; Eling Gaines; Sonja Heintz; Thomas A Bicsak; Kristin Taylor; Dennis Kim; Maria Aisporna; Yan Wang; Alain D Baron
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

Review 7.  Exenatide efficacy and safety: a systematic review.

Authors:  S L Norris; N Lee; S Thakurta; B K S Chan
Journal:  Diabet Med       Date:  2009-09       Impact factor: 4.359

8.  Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

Authors:  Mark S Fineman; Thomas A Bicsak; Larry Z Shen; Kristin Taylor; Eling Gaines; Amanda Varns; Dennis Kim; Alain D Baron
Journal:  Diabetes Care       Date:  2003-08       Impact factor: 19.112

Review 9.  Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.

Authors:  David M Kendall; Robert M Cuddihy; Richard M Bergenstal
Journal:  Eur J Intern Med       Date:  2009-06-24       Impact factor: 4.487

10.  One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.

Authors:  Mathijs C Bunck; Michaela Diamant; Anja Cornér; Bjorn Eliasson; Jaret L Malloy; Rimma M Shaginian; Wei Deng; David M Kendall; Marja-Riitta Taskinen; Ulf Smith; Hannele Yki-Järvinen; Robert J Heine
Journal:  Diabetes Care       Date:  2009-02-05       Impact factor: 17.152

  10 in total
  7 in total

Review 1.  Adverse Effects of GLP-1 Receptor Agonists.

Authors:  Theodosios D Filippatos; Thalia V Panagiotopoulou; Moses S Elisaf
Journal:  Rev Diabet Stud       Date:  2015-02-10

Review 2.  Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

Review 3.  Effects of glucagon-like peptide-1 receptor agonists on renal function.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Diabetes       Date:  2013-10-15

4.  Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.

Authors:  Katherine R Tuttle; T Dwight McKinney; Jaime A Davidson; Greg Anglin; Kristine D Harper; Fady T Botros
Journal:  Diabetes Obes Metab       Date:  2016-11-24       Impact factor: 6.577

Review 5.  GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?

Authors:  S Brunton
Journal:  Int J Clin Pract       Date:  2014-02-06       Impact factor: 2.503

Review 6.  GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.

Authors:  Matthew P Gilbert; Richard E Pratley
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-03       Impact factor: 5.555

Review 7.  Safety of Semaglutide.

Authors:  Mark M Smits; Daniël H Van Raalte
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-07       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.